Wiele, A.J.; Surasi, D.S.; Rao, P.; Sircar, K.; Su, X.; Bathala, T.K.; Shah, A.Y.; Jonasch, E.; Cataldo, V.D.; Genovese, G.;
et al. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers 2021, 13, 2170.
https://doi.org/10.3390/cancers13092170
AMA Style
Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G,
et al. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers. 2021; 13(9):2170.
https://doi.org/10.3390/cancers13092170
Chicago/Turabian Style
Wiele, Andrew J., Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese,
and et al. 2021. "Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma" Cancers 13, no. 9: 2170.
https://doi.org/10.3390/cancers13092170
APA Style
Wiele, A. J., Surasi, D. S., Rao, P., Sircar, K., Su, X., Bathala, T. K., Shah, A. Y., Jonasch, E., Cataldo, V. D., Genovese, G., Karam, J. A., Wood, C. G., Tannir, N. M., & Msaouel, P.
(2021). Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers, 13(9), 2170.
https://doi.org/10.3390/cancers13092170